Table 7.
Percentage of responding panel members (N = 6) who recommended that treatment should be initiated, based on evaluation of each case history against PREDICT-FD criteria, EFWG guidance, and their own country’s guidelines
| Case | PREDICT-FD | EFWG | Country | Case | PREDICT-FD | EFWG | Country |
|---|---|---|---|---|---|---|---|
| 1 | 3 (60) | 2 (50) | 3 (60) | 10 | 2 (50) | 1 (25) | 2 (40) |
| 2 | 4 (100) | 4 (100) | 4 (100) | 11 | 2 (67) | 2 (67) | 3 (75) |
| 3 | 3 (100) | 1 (33) | 1 (33) | 12 | 2 (67) | 3 (100) | 4 (100) |
| 4 | 3 (100) | 3 (100) | 3 (100) | 13 | 2 (100) | 2 (100) | 4 (100) |
| 5 | 2 (67) | 2 (67) | 2 (67) | 14 | 3 (100) | 3 (100) | 4 (100) |
| 6 | 3 (100) | 3 (100) | 4 (100) | 15 | 2 (100) | 2 (100) | 2 (67) |
| 7 | 2 (100) | 2 (100) | 3 (100) | 16 | 2 (100) | 2 (100) | 3 (100) |
| 8 | 1 (33) | 1 (33) | 1 (25) | 17 | 2 (100) | 2 (100) | 3 (100) |
| 9 | 1 (50) | 1 (50) | 2 (67) |
Data are n (%). Shaded rows indicate cases for which disease-specific therapy initiation was recommended unanimously, irrespective of which set of guidelines was used
EFWG, European Fabry Working Group; PREDICT-FD, PRoposing Early Disease Indicators for Clinical Tracking in Fabry Disease